Literature DB >> 34313331

Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI).

Ingrid Arevalo-Rodriguez1, Nadja Smailagic2, Marta Roqué-Figuls3, Agustín Ciapponi4, Erick Sanchez-Perez5, Antri Giannakou6, Olga L Pedraza5, Xavier Bonfill Cosp7, Sarah Cullum8.   

Abstract

BACKGROUND: Dementia is a progressive global cognitive impairment syndrome. In 2010, more than 35 million people worldwide were estimated to be living with dementia. Some people with mild cognitive impairment (MCI) will progress to dementia but others remain stable or recover full function. There is great interest in finding good predictors of dementia in people with MCI. The Mini-Mental State Examination (MMSE) is the best-known and the most often used short screening tool for providing an overall measure of cognitive impairment in clinical, research and community settings.
OBJECTIVES: To determine the accuracy of the Mini Mental State Examination for the early detection of dementia in people with mild cognitive impairment SEARCH
METHODS: We searched ALOIS (Cochrane Dementia and Cognitive Improvement Specialized Register of diagnostic and intervention studies (inception to May 2014); MEDLINE (OvidSP) (1946 to May 2014); EMBASE (OvidSP) (1980 to May 2014); BIOSIS (Web of Science) (inception to May 2014); Web of Science Core Collection, including the Conference Proceedings Citation Index (ISI Web of Science) (inception to May 2014); PsycINFO (OvidSP) (inception to May 2014), and LILACS (BIREME) (1982 to May 2014). We also searched specialized sources of diagnostic test accuracy studies and reviews, most recently in May 2014: MEDION (Universities of Maastricht and Leuven, www.mediondatabase.nl), DARE (Database of Abstracts of Reviews of Effects, via the Cochrane Library), HTA Database (Health Technology Assessment Database, via the Cochrane Library), and ARIF (University of Birmingham, UK, www.arif.bham.ac.uk). No language or date restrictions were applied to the electronic searches and methodological filters were not used as a method to restrict the search overall so as to maximize sensitivity. We also checked reference lists of relevant studies and reviews, tracked citations in Scopus and Science Citation Index, used searches of known relevant studies in PubMed to track related articles, and contacted research groups conducting work on MMSE for dementia diagnosis to try to locate possibly relevant but unpublished data. SELECTION CRITERIA: We considered longitudinal studies in which results of the MMSE administered to MCI participants at baseline were obtained and the reference standard was obtained by follow-up over time. We included participants recruited and clinically classified as individuals with MCI under Petersen and revised Petersen criteria, Matthews criteria, or a Clinical Dementia Rating = 0.5. We used acceptable and commonly used reference standards for dementia in general, Alzheimer's dementia, Lewy body dementia, vascular dementia and frontotemporal dementia. DATA COLLECTION AND ANALYSIS: We screened all titles generated by the electronic database searches. Two review authors independently assessed the abstracts of all potentially relevant studies. We assessed the identified full papers for eligibility and extracted data to create two by two tables for dementia in general and other dementias. Two authors independently performed quality assessment using the QUADAS-2 tool. Due to high heterogeneity and scarcity of data, we derived estimates of sensitivity at fixed values of specificity from the model we fitted to produce the summary receiver operating characteristic curve. MAIN
RESULTS: In this review, we included 11 heterogeneous studies with a total number of 1569 MCI patients followed for conversion to dementia. Four studies assessed the role of baseline scores of the MMSE in conversion from MCI to all-cause dementia and eight studies assessed this test in conversion from MCI to Alzheimer´s disease dementia. Only one study provided information about the MMSE and conversion from MCI to vascular dementia. For conversion from MCI to dementia in general, the accuracy of baseline MMSE scores ranged from sensitivities of 23% to 76% and specificities from 40% to 94%. In relationship to conversion from MCI to Alzheimer's disease dementia, the accuracy of baseline MMSE scores ranged from sensitivities of 27% to 89% and specificities from 32% to 90%. Only one study provided information about conversion from MCI to vascular dementia, presenting a sensitivity of 36% and a specificity of 80% with an incidence of vascular dementia of 6.2%. Although we had planned to explore possible sources of heterogeneity, this was not undertaken due to the scarcity of studies included in our analysis. AUTHORS'
CONCLUSIONS: Our review did not find evidence supporting a substantial role of MMSE as a stand-alone single-administration test in the identification of MCI patients who could develop dementia. Clinicians could prefer to request additional and extensive tests to be sure about the management of these patients. An important aspect to assess in future updates is if conversion to dementia from MCI stages could be predicted better by MMSE changes over time instead of single measurements. It is also important to assess if a set of tests, rather than an isolated one, may be more successful in predicting conversion from MCI to dementia.
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2021        PMID: 34313331      PMCID: PMC8406467          DOI: 10.1002/14651858.CD010783.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  109 in total

1.  The death knoll for the MMSE: has it outlived its purpose?

Authors:  Ruth E Nieuwenhuis-Mark
Journal:  J Geriatr Psychiatry Neurol       Date:  2010-03-15       Impact factor: 2.680

2.  A unification of models for meta-analysis of diagnostic accuracy studies.

Authors:  Roger M Harbord; Jonathan J Deeks; Matthias Egger; Penny Whiting; Jonathan A C Sterne
Journal:  Biostatistics       Date:  2006-05-11       Impact factor: 5.899

3.  The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease.

Authors:  Paul B Rosenberg; Michelle M Mielke; Brian S Appleby; Esther S Oh; Yonas E Geda; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

Review 4.  Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

5.  Progression to dementia in a population with amnestic mild cognitive impairment: clinical variables associated with conversion.

Authors:  Marco Mauri; Elena Sinforiani; Chiara Zucchella; Maria Giovanna Cuzzoni; Giorgio Bono
Journal:  Funct Neurol       Date:  2012 Jan-Mar

6.  Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI.

Authors:  M Ewers; K Buerger; S J Teipel; P Scheltens; J Schröder; R P Zinkowski; F H Bouwman; P Schönknecht; N S M Schoonenboom; N Andreasen; A Wallin; J F DeBernardis; D J Kerkman; B Heindl; K Blennow; H Hampel
Journal:  Neurology       Date:  2007-12-11       Impact factor: 9.910

Review 7.  Diagnosis and treatment of dementia: 2. Diagnosis.

Authors:  Howard H Feldman; Claudia Jacova; Alain Robillard; Angeles Garcia; Tiffany Chow; Michael Borrie; Hyman M Schipper; Mervin Blair; Andrew Kertesz; Howard Chertkow
Journal:  CMAJ       Date:  2008-03-25       Impact factor: 8.262

8.  Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease.

Authors:  Davangere P Devanand; Xinhua Liu; Matthias H Tabert; Gnanavalli Pradhaban; Katrina Cuasay; Karen Bell; Mony J de Leon; Richard L Doty; Yaakov Stern; Gregory H Pelton
Journal:  Biol Psychiatry       Date:  2008-08-23       Impact factor: 13.382

9.  Mini-mental State Examination performance in mild cognitive impairment subtypes.

Authors:  Breno S O Diniz; Monica S Yassuda; Paula V Nunes; Marcia Radanovic; Orestes V Forlenza
Journal:  Int Psychogeriatr       Date:  2007-05-14       Impact factor: 3.878

Review 10.  Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias.

Authors:  Daniel H J Davis; Sam T Creavin; Jennifer L Y Yip; Anna H Noel-Storr; Carol Brayne; Sarah Cullum
Journal:  Cochrane Database Syst Rev       Date:  2015-10-29
View more
  15 in total

1.  Prevalence of potentially inappropriate medications among old people with major neurocognitive disorder in 2012 and 2017.

Authors:  Iris Rangfast; Eva Sönnerstam; Maria Gustafsson
Journal:  BMC Geriatr       Date:  2022-06-30       Impact factor: 4.070

2.  Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer's Disease.

Authors:  Chiara Fornari; Francesco Mori; Nicola Zoppi; Ilenia Libri; Chiara Silvestri; Maura Cosseddu; Rosanna Turrone; Matteo Maffi; Salvatore Caratozzolo; Barbara Borroni; Alessandro Padovani; Alberto Benussi
Journal:  Neurol Int       Date:  2022-04-06

3.  Machine Learning Reveals a Multipredictor Nomogram for Diagnosing the Alzheimer's Disease Based on Chemiluminescence Immunoassay for Total Tau in Plasma.

Authors:  Lingyu Zhang; Danhua Wang; Yibei Dai; Xuchu Wang; Ying Cao; Weiwei Liu; Zhihua Tao
Journal:  Front Aging Neurosci       Date:  2022-05-13       Impact factor: 5.702

4.  Functional and structural brain network correlates of visual hallucinations in Lewy body dementia.

Authors:  Ramtin Mehraram; Luis R Peraza; Nicholas R E Murphy; Ruth A Cromarty; Sara Graziadio; John T O'Brien; Alison Killen; Sean J Colloby; Michael Firbank; Li Su; Daniel Collerton; John Paul Taylor; Marcus Kaiser
Journal:  Brain       Date:  2022-06-30       Impact factor: 15.255

Review 5.  Pathogenic mechanisms and therapeutic promise of phytochemicals and nanocarriers based drug delivery against radiotherapy-induced neurotoxic manifestations.

Authors:  Ashif Iqubal; Mohammad Kashif Iqubal; Sumit Sharma; Mohd Wasim; Mohamed A Alfaleh; Shadab Md; Sanjula Baboota; Javed Ali; Syed Ehtaishamul Haque
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

6.  Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis.

Authors:  Natalia Ogonowski; Stefanny Salcidua; Tomas Leon; Nayaret Chamorro-Veloso; Cristian Valls; Constanza Avalos; Alejandro Bisquertt; Miguel E Rentería; Paulina Orellana; Claudia Duran-Aniotz
Journal:  Front Aging Neurosci       Date:  2022-01-12       Impact factor: 5.750

7.  Staging Disease Severity Using the Alzheimer's Disease Composite Score (ADCOMS): A Retrospective Data Analysis.

Authors:  Amir Abbas Tahami Monfared; Katherine Houghton; Quanwu Zhang; Josephine Mauskopf
Journal:  Neurol Ther       Date:  2022-01-31

8.  Cognitive impairment in the population-based ural very old study.

Authors:  Mukharram M Bikbov; Gyulli M Kazakbaeva; Ellina M Iakupova; Songhomitra Panda-Jonas; Albina A Fakhretdinova; Azaliia M Tuliakova; Iuliia A Rusakova; Jost B Jonas
Journal:  Front Aging Neurosci       Date:  2022-07-19       Impact factor: 5.702

Review 9.  Epigenetics in Alzheimer's Disease.

Authors:  Xiaodie Gao; Qiang Chen; Hua Yao; Jie Tan; Zheng Liu; Yan Zhou; Zhenyou Zou
Journal:  Front Aging Neurosci       Date:  2022-06-23       Impact factor: 5.702

10.  Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model.

Authors:  Qiang Liu; Nemanja Vaci; Ivan Koychev; Andrey Kormilitzin; Zhenpeng Li; Andrea Cipriani; Alejo Nevado-Holgado
Journal:  BMC Med       Date:  2022-02-01       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.